<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791517</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5230</org_study_id>
    <nct_id>NCT01791517</nct_id>
  </id_info>
  <brief_title>Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions</brief_title>
  <official_title>Clinical and Laboratory Evaluation of Three Contact Lens Materials With Four Contact Lens Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical and laboratory performance of three
      brand name contact lenses with three recently introduced multipurpose lens care solutions
      (test solutions) as well as a peroxide disinfecting solution (control solution).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Actual">February 1, 2014</completion_date>
  <primary_completion_date type="Actual">February 1, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Comfort Score (Senofilcon A Lens)</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the senofilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Comfort Score (Galyfilcon A Lens)</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the galyfilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Comfort Score (Etafilcon A Lens)</measure>
    <time_frame>2-Week Follow-up</time_frame>
    <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the etafilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">269</enrollment>
  <condition>Contact Lens Solutions</condition>
  <arm_group>
    <arm_group_label>Lens A (senofilcon A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens B (galyfilcon A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens C (etafilcon A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solution 1 (Test)</intervention_name>
    <description>Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order</description>
    <arm_group_label>Lens A (senofilcon A)</arm_group_label>
    <arm_group_label>Lens B (galyfilcon A)</arm_group_label>
    <arm_group_label>Lens C (etafilcon A)</arm_group_label>
    <other_name>Revitalens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solution 2 (Test)</intervention_name>
    <description>Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order</description>
    <arm_group_label>Lens A (senofilcon A)</arm_group_label>
    <arm_group_label>Lens B (galyfilcon A)</arm_group_label>
    <arm_group_label>Lens C (etafilcon A)</arm_group_label>
    <other_name>Pure Moist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solution 3 (Test)</intervention_name>
    <description>Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order</description>
    <arm_group_label>Lens A (senofilcon A)</arm_group_label>
    <arm_group_label>Lens B (galyfilcon A)</arm_group_label>
    <arm_group_label>Lens C (etafilcon A)</arm_group_label>
    <other_name>Biotrue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solution 4 (Control)</intervention_name>
    <description>Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order</description>
    <arm_group_label>Lens A (senofilcon A)</arm_group_label>
    <arm_group_label>Lens B (galyfilcon A)</arm_group_label>
    <arm_group_label>Lens C (etafilcon A)</arm_group_label>
    <other_name>Clear Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
             receive a fully executed copy of the form.

          2. The subject must appear able and willing to adhere to the instruction set forth in
             this clinical protocol.

          3. The subject must be between 18 and 69 years of age.

          4. The subject must be willing to participate in a 9-month study.

          5. The subject must require a visual correction in both eyes.

          6. Subjective refraction must result in a vertex-corrected spherical contact lens
             prescription of +2.00D to -8.00D in each eye.

          7. The subject must have best-corrected visual acuity of 0.20 or better in each eye.

          8. The subject must be a current wearer of spherical soft contact lenses (no bifocal
             contact lenses or monovision) for at least 5 days/week and at least 8 hours/day during
             the month prior to enrollment.

          9. The subject must require no more than -1.25D cylindrical correction in each eye after
             vertexing to the corneal plane.

         10. The subject must have normal eye with no evidence of abnormality or disease that in
             the opinion of the investigator would contraindicate contact lens wear.

        Exclusion Criteria:

          1. Self-reported current pregnancy or lactation or plans to become pregnant during the
             study period (subjects who report becoming pregnant during the study will be
             discontinued).

          2. Self-reported adverse reaction to a contact lens solution to be used in the study that
             in the opinion of the investigator would contraindicate use of that solution.

          3. Any previous ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.).

          4. Any clinically meaningful slit lamp findings contraindicating contact lens wear (e.g.
             equal to or greater than Grade 3 finding of edema, corneal neovascularization, corneal
             staining, tarsal abnormalities, conjunctival injection, blepharitis/meibomian gland
             dysfunction) on the study specific classification scale or any other ocular
             abnormality that in the opinion of the investigator would contraindicate contact lens
             wear.

          5. Any active ocular infection.

          6. Current use of topical ophthalmic medications.

          7. History of binocular vision abnormality or strabismus.

          8. More than occasional use of dry eye/rewetting drops (more than 2 times per day on
             average).

          9. Any infectious disease (e.g. hepatitis, tuberculosis) or a contagious
             immunosuppressive disease (e.g. HIV) by self-report.

         10. History of severe allergic reaction or anaphylaxis.

         11. Other active ocular disease that in the opinion of the investigator would
             contraindicate contact lens wear.

         12. Employee of the investigational clinic (e.g. investigator, coordinator, technician)

         13. They have taken part in any other clinical trial or research, within two weeks prior
             to starting this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Houston College of Optometry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Waterloo Centre for Contact Lens Research School of Optometry</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester, Department of Optometry &amp; Neuroscience</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>August 16, 2017</results_first_submitted>
  <results_first_submitted_qc>October 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Contact Lens Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 269 Subjects were enrolled into this study. Of the enrolled 33 subjects did not meet the eligibility criteria. In Phase I 28 subjects were discontinued and 208 subjects completed Phase I. Of the 208 subjects that continued into Phase II 187 subjects completed the study and 21 subjects were discontinued from the from Phase II.</recruitment_details>
      <pre_assignment_details>Subjects were first randomized to 1 of 3 lenses(Lens A: senofilcon A, Lens B: galyfilcon A, Lens C: etafilcon A), then within each lens subjects were randomized to 1 of 12 unique solution sequences, totaling in 36 sequences. Due to such a large number of sequences for reporting purposes, subject disposition is reported by solution and period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Biotrue/PureMoist/Revitalens/Clear Care</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P2">
          <title>Biotrue/RevitaLens/Clear Care/PureMoist</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P3">
          <title>Biotrue/Clear Care/PureMoist/RevitaLens</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P4">
          <title>PureMoist/Biotrue/Clear Care/RevitaLens</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P5">
          <title>PureMoist/RevitaLens/Biotrue/Clear Care</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P6">
          <title>PureMoist/Clear Care/RevitaLens/Biotrue</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P7">
          <title>RevitaLens/Biotrue/PureMoist/Clear Care</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P8">
          <title>RevitaLens/PureMoist/Clear Care/Biotrue</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P9">
          <title>RevitaLens/Clear Care/Biotrue/PureMoist</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P10">
          <title>Clear Care/Biotrue/RevitaLens/PureMoist</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P11">
          <title>Clear Care/PureMoist/Biotrue/RevitaLens</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
        <group group_id="P12">
          <title>Clear Care/RevitaLens/PureMoist/Biotrue</title>
          <description>Subjects were first randomized to receive to one of three lenses lens. For Phase I subjects were then further randomized to one of twelve unique solution sequences.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I: Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="18"/>
                <participants group_id="P12" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="18"/>
                <participants group_id="P12" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fitting</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Handling DIfficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I: Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="18"/>
                <participants group_id="P12" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Visual Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I: Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lens Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I: Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="20"/>
                <participants group_id="P9" count="19"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="17"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="15"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lens Handling Difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory Lens Fitting</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-Existing Ocular Issue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population consists of subjects that were randomized to 1 of 3 study lenses and 1 of 12 solution sequences.</population>
      <group_list>
        <group group_id="B1">
          <title>Etafilcon A</title>
          <description>All subjects that were randomized to the study lens etafilcon A and 1 of 12 possible solution sequences.</description>
        </group>
        <group group_id="B2">
          <title>Galyfilcon A</title>
          <description>All subjects that were randomized to the study lens galyfilcon A and 1 of 12 possible solution sequences.</description>
        </group>
        <group group_id="B3">
          <title>Senofilcon A</title>
          <description>All subjects that were randomized to the study lens senofilcon A and 1 of 12 possible solution sequences.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.33" spread="9.726"/>
                    <measurement group_id="B2" value="30.38" spread="10.091"/>
                    <measurement group_id="B3" value="29.78" spread="9.938"/>
                    <measurement group_id="B4" value="30.17" spread="9.879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort Score (Senofilcon A Lens)</title>
        <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the senofilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution 1(RevitaLens)</title>
            <description>Subjects that received solution 1 during any of the 4 study periods.</description>
          </group>
          <group group_id="O2">
            <title>Solution 2(PureMoist)</title>
            <description>Subjects that received solution 2 during any of the 4 study periods.</description>
          </group>
          <group group_id="O3">
            <title>Solution 3(Biotrue)</title>
            <description>Subjects that received solution 3 during any of the 4 study periods.</description>
          </group>
          <group group_id="O4">
            <title>Solution 4(Clear Care)</title>
            <description>Subjects that received solution 4 during any of the 4 study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort Score (Senofilcon A Lens)</title>
          <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the senofilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
          <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.42" spread="22.536"/>
                    <measurement group_id="O2" value="59.73" spread="25.470"/>
                    <measurement group_id="O3" value="63.75" spread="21.796"/>
                    <measurement group_id="O4" value="63.47" spread="23.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort Score (Galyfilcon A Lens)</title>
        <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the galyfilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution 1(RevitaLens)</title>
            <description>Subjects that received solution 1 during any of the 4 study periods.</description>
          </group>
          <group group_id="O2">
            <title>Solution 2(PureMoist)</title>
            <description>Subjects that received solution 2 during any of the 4 study periods.</description>
          </group>
          <group group_id="O3">
            <title>Solution 3(Biotrue)</title>
            <description>Subjects that received solution 3 during any of the 4 study periods.</description>
          </group>
          <group group_id="O4">
            <title>Solution 4(Clear Care)</title>
            <description>Subjects that received solution 4 during any of the 4 study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort Score (Galyfilcon A Lens)</title>
          <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the galyfilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
          <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.79" spread="23.430"/>
                    <measurement group_id="O2" value="56.95" spread="24.679"/>
                    <measurement group_id="O3" value="58.52" spread="22.197"/>
                    <measurement group_id="O4" value="59.83" spread="22.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort Score (Etafilcon A Lens)</title>
        <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the etafilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
        <time_frame>2-Week Follow-up</time_frame>
        <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution 1(RevitaLens)</title>
            <description>Subjects that received solution 1 during any of the 4 study periods.</description>
          </group>
          <group group_id="O2">
            <title>Solution 2(PureMoist)</title>
            <description>Subjects that received solution 2 during any of the 4 study periods.</description>
          </group>
          <group group_id="O3">
            <title>Solution 3(Biotrue)</title>
            <description>Subjects that received solution 3 during any of the 4 study periods.</description>
          </group>
          <group group_id="O4">
            <title>Solution 4(Clear Care)</title>
            <description>Subjects that received solution 4 during any of the 4 study periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort Score (Etafilcon A Lens)</title>
          <description>CLUE overall comfort is assessed using the Contact Lens User Experience (CLUE)TM questionnaire for the etafilcon A lens only. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).</description>
          <population>The analysis population consists of all subjects that have completed all study visits without a major protocol deviation. The number of subjects reported above is the maximum number of subjects for that solution. The number of subjects may vary per solution/lens combination, since this study was stratified by contact lens.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.57" spread="25.158"/>
                    <measurement group_id="O2" value="67.44" spread="19.65"/>
                    <measurement group_id="O3" value="62.43" spread="21.492"/>
                    <measurement group_id="O4" value="65.33" spread="21.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 52 weeks.</time_frame>
      <desc>Adverse events from Phase I and Phase II are reported together due to the large number of lens and solution combinations.</desc>
      <group_list>
        <group group_id="E1">
          <title>Solution 1(RevitaLens): Senofilcon A</title>
          <description>Subjects that were randomized to the senofilcon A lens and received solution 1 during any of the 4 study periods.</description>
        </group>
        <group group_id="E2">
          <title>Solution 1 (RevitaLens): Galyfilcon A</title>
          <description>Subjects that were randomized to the galyfilcon A lens and received solution 1 during any of the 4 study periods.</description>
        </group>
        <group group_id="E3">
          <title>Solution 1(RevitaLens): Etafilcon A</title>
          <description>Subjects that were randomized to the etafilcon A lens and received solution 1 during any of the 4 study periods.</description>
        </group>
        <group group_id="E4">
          <title>Solution 2(PureMoist):Senofilcon A</title>
          <description>Subjects were randomized to the senofilcon A lens and that received solution 2 during any of the 4 study periods.</description>
        </group>
        <group group_id="E5">
          <title>Solution 2(PureMoist): Galyfilcon A</title>
          <description>Subjects were randomized to the galyfilcon A lens and that received solution 2 during any of the 4 study periods.</description>
        </group>
        <group group_id="E6">
          <title>Solution 2(PureMoist): Etafilcon A</title>
          <description>Subjects were randomized to the etafilcon A lens and that received solution 2 during any of the 4 study periods.</description>
        </group>
        <group group_id="E7">
          <title>Solution 3(Biotrue): Senofilcon A</title>
          <description>Subjects that were randomized to the senofilcon A lens and received solution 3 during any of the 4 study periods.</description>
        </group>
        <group group_id="E8">
          <title>Solution 3(Biotrue): Galyfilcon A</title>
          <description>Subjects that were randomized to the galyfilcon A lens and received solution 3 during any of the 4 study periods.</description>
        </group>
        <group group_id="E9">
          <title>Solution 3(Biotrue): Etafilcon A</title>
          <description>Subjects that were randomized to the etafilcon A lens and received solution 3 during any of the 4 study periods.</description>
        </group>
        <group group_id="E10">
          <title>Solution 4(Clear Care): Senofilcon A</title>
          <description>Subjects that were randomized to the senofilcon A lens and received solution 4 during any of the 4 study periods.</description>
        </group>
        <group group_id="E11">
          <title>Solution 4(Clear Care): Galyfilcon A</title>
          <description>Subjects that were randomized to the galyfilcon A lens and received solution 4 during any of the 4 study periods.</description>
        </group>
        <group group_id="E12">
          <title>Solution 4(Clear Care): Etafilcon A</title>
          <description>Subjects that were randomized to the etafilcon A lens and received solution 4 during any of the 4 study periods.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Retro-peritoneal abscess in the kidney area.</sub_title>
                <description>According to the participant, his doctors hypothesized that the development of the abscess may be related to a perforated appendix he had in November 2011. This adverse event was deemed unrelated to the study by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Viral Meningitis</sub_title>
                <description>Suspect viral meningitis. Had severe vomiting and headaches. Subject admitted to hospital. This was deemed unrelated to the study by the investigator.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Subject experienced two seizures, on August 03, 2013 to August 04, 2013. Subject has a history of seizures and stopped taking medicine(without doctor's approval). The adverse event was deemed unrelated to the study by the investigator.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Health / Phychiatric Hospital Admission</sub_title>
                <description>Subject's discontinuation of seizure medication and mental health status and was admitted to the hospital on August 03, 2013. The adverse event was deemed unrelated to the study by the investigator.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reconstructive Surgery on Left Upper Arm</sub_title>
                <description>This event was deemed unrelated to the study by the investigator.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chantal Coles-Brennan, PRINCIPAL RESEARCH OPTOMETRIST, Global Med Affairs</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care, Inc.</organization>
      <phone>904-443-3500 ext 3449</phone>
      <email>CColesb@ITS.JNJ.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

